Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2022 | Recent advances in the use of targeted therapies for metastatic urothelial carcinoma

Yohann Loriot, MD, PhD, Gustave Roussy, Villejuif, France, and University of Paris-Saclay, Gif-sur-Yvette, France, discusses up and coming targeted agents in the field of metastatic urothelial carcinoma (mUC), including for FGFR, NECTIN4, TRP-2 and HER2. Promising data demonstrated an overall response rate (ORR) of 30% with sacituzumab govitecan, a Trop-2 targeting agent, in a Phase II trial and trastuzumab plus pembrolizumab has also demonstrated some promising activity. The antibody drug conjugate (ADC), ARC48, targeting HER2 has also shown activity in the metastatic setting of bladder cancer. This interview took place at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium 2022 in San Francisco, CA.